1.To describe advancements in molecularly targeted therapies for cancer, including novel inhibitor of Glycogen synthase kinase 3 beta.

2.To define the evolving field of novel combinations of immunotherapy drugs and biomarkers for tumor response.


Session date: 
01/25/2019 - 8:00am to 9:00am CST
NorthShore - Evanston
Evanston, IL 60201
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Benedito Carneiro, MD